Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Dosage Forms × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Other solid neoplasm 1 Other hematologic neoplasm 1 Genitourinary 1 CNS 1

Conditions

Recurrence 1 Multiple Myeloma 1

Interventions

Dexamethasone 288 Lenalidomide 160 Bortezomib 160 Cyclophosphamide 120 Calcium Dobesilate 118 Melphalan 116 fludarabine phosphate 75 carfilzomib 61 Whole-Body Irradiation 57 Mycophenolic Acid 55 Granulocyte Colony-Stimulating Factor 55 Peripheral Blood Stem Cell Transplantation 54 Filgrastim 54 pomalidomide 53 fludarabine 50 daratumumab 46 Tacrolimus 45 Busulfan 45 ixazomib 42 Thalidomide 37 Cyclosporine 31 Stem Cell Transplantation 29 dexamethasone acetate 28 Antilymphocyte Serum 26 dexamethasone 21-phosphate 23 plerixafor 21 elotuzumab 20 auricularum 20 Prednisone 19 Etoposide 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02939183 2024-09-26

INTREPID-1

Amgen

Phase 1 Completed

61 enrolled 28 charts

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡